TEZSPIRE AstraZeneca Pty Ltd
Product name
TEZSPIRE
Sponsor
Accepted date
Sep-2025
Active ingredients
tezepelumab
Proposed indication
Tezspire (tezepelumab) is proposed for the treatment in adult patients of chronic rhinosinusitis with nasal polyps, an inflammatory condition affecting the sinuses that is accompanied by nasal polyps—soft, noncancerous growths inside the nose and sinuses.
Application type
C (new indication)
Publication date
Sep-2025